started · updated
Chile approves Picmagluti as semaglutide alternative
Chile’s Public Health Institute (ISP) has approved Picmagluti, an injectable medication developed by Dr. Reddy’s Laboratories Chile. This marks the first semaglutide obtained through chemical synthesis to receive sanitary registration in the country.
The ISP granted two sanitary registrations for the drug: one for doses of 0.25 mg or 0.5 mg, and another for the 1 mg presentation. While semaglutide is widely known for weight management, the approved indication for Picmagluti is specifically as a complementary treatment to diet and exercise for adults with type 2 diabetes whose glycemic control is insufficient.
Unlike Ozempic, which is registered in Chile as a biological product, Picmagluti is manufactured via chemical synthesis. Health authorities emphasized that the presence of the same active ingredient does not make the medications automatically interchangeable and that all treatments must be managed under medical supervision.
Entities
Chile · Dr. Reddy’s Laboratories Chile · Picmagluti · Public Health Institute of Chile